Inovio Pharmaceuticals Inc (INO) was Downgraded by Maxim Group to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Maxim Group advised their investors in a research report released on Aug 9, 2016.
On the company’s financial health, Inovio Pharmaceuticals Inc reported $-0.26 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.21. The company had revenue of $6.20 million for the quarter, compared to analysts expectations of $4.95 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
Inovio Pharmaceuticals Inc closed down -0.5 points or -5.08% at $9.35 with 21,59,298 shares getting traded on Monday. Post opening the session at $9.9, the shares hit an intraday low of $9.12 and an intraday high of $9.95 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 29, 2016, Morton Collins (director) purchased 10,000 shares at $9.13 per share price. According to the SEC, on May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price. On Sep 30, 2015, Niranjan Sardesai (COO) purchased 4,000 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.